Next Article in Journal
The Supportive Care Needs of Regional and Remote Cancer Caregivers
Previous Article in Journal
SOX2 and Bcl-2 as a Novel Prognostic Value in Hepatocellular Carcinoma Progression
Article

Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer

1
St. Michael’s Hospital, 30 Bond St, Toronto, ON M5B 1W8, Canada
2
Medical Sciences Building, 1 King’s College Circle, University of Toronto, Toronto, ON M5S 1A8, Canada
3
Mount Sinai Hospital, 1284-600 University Avenue, Toronto, ON M5G 1X5, Canada
4
Lunenfeld-Tanenbaum Research Institute, 600 University Ave, Toronto, ON M5G 1X5, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(4), 3030-3040; https://doi.org/10.3390/curroncol28040265
Received: 31 May 2021 / Revised: 31 July 2021 / Accepted: 4 August 2021 / Published: 9 August 2021
Chemotherapy-associated steatosis is poorly understood in the context of colorectal cancer. In this study, Stage II–III colorectal cancer patients were retrospectively selected to evaluate the frequency of chemotherapy-associated steatosis and to determine whether patients on statins throughout adjuvant chemotherapy develop chemotherapy-associated steatosis at a lower frequency. Baseline and incident steatosis for up to one year from chemotherapy start date was assessed based on radiology. Of 269 patients, 76 (28.3%) had steatosis at baseline. Of the remaining 193 cases, patients receiving adjuvant chemotherapy (n = 135) had 1.57 (95% confidence interval [CI], 0.89 to 2.79) times the adjusted risk of developing steatosis compared to patients not receiving chemotherapy (n = 58). Among patients who underwent chemotherapy, those using statins for pre-existing hyperlipidemia (n = 37) had 0.71 (95% CI, 0.10 to 2.75) times the risk of developing steatosis compared to patients who were not prevalent users of statins (n = 98). Chemotherapeutic treatment of Stage II–III colorectal cancer appears to be consistent with a moderately increased risk of steatosis, although larger studies are necessary to assess the significance of this observation. Prospective trials should be considered to further explore the potential for protective use of statins in this curative patient population. View Full-Text
Keywords: fatty liver; chemotherapy; colorectal neoplasm fatty liver; chemotherapy; colorectal neoplasm
Show Figures

Figure 1

MDPI and ACS Style

Lee, M.C.M.; Kachura, J.J.; Vlachou, P.A.; Dzulynsky, R.; Di Tomaso, A.; Samawi, H.; Baxter, N.; Brezden-Masley, C. Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer. Curr. Oncol. 2021, 28, 3030-3040. https://doi.org/10.3390/curroncol28040265

AMA Style

Lee MCM, Kachura JJ, Vlachou PA, Dzulynsky R, Di Tomaso A, Samawi H, Baxter N, Brezden-Masley C. Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer. Current Oncology. 2021; 28(4):3030-3040. https://doi.org/10.3390/curroncol28040265

Chicago/Turabian Style

Lee, Michelle C.M., Jacob J. Kachura, Paraskevi A. Vlachou, Raissa Dzulynsky, Amy Di Tomaso, Haider Samawi, Nancy Baxter, and Christine Brezden-Masley. 2021. "Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer" Current Oncology 28, no. 4: 3030-3040. https://doi.org/10.3390/curroncol28040265

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop